Assessment of Labile Plasma Iron in Patients Who Undergo Hematopoietic Stem Cell Transplantation

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Acta Haematologica

• Publication date

  2013-12-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000355192PMID 24335268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• chelation Labile plasma iron in iron overload: redox activity and susceptibility to

  2013cited by this paper
• Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

  2012cited by this paper
• Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

  2011cited by this paper
• Transferrin therapy ameliorates disease in β-thalassemic mice

  2010cited by this paper
• Non‐transferrin‐bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation

  2009cited by this paper
• Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients

  2009cited by this paper
• Iron overload following red blood cell transfusion and its impact on disease severity.

  2009cited by this paper
• Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

  2009cited by this paper
• Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-beta thalassemia.

  2008cited by this paper
• Iron overload in hematopoietic cell transplantation

  2008cited by this paper
• Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation

  2008cited by this paper
• Endothelial Dysfunction and Oxidant Status in Pediatric Patients with Hemoglobin E-β Thalassemia

  2007cited by this paper
• Iron, oxidative stress and early neurological deterioration in ischemic stroke.

  2007cited by this paper
• LPI-labile plasma iron in iron overload.

  2005cited by this paper
• Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants?

  2005cited by this paper
• Oxidative stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell transplantation

  2004cited by this paper
• Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes.

  2004cited by this paper
• Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress

  2004cited by this paper
• Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0

  2004cited by this paper
• Non-protein bound iron release during chemotherapy in cancer patients.

  2004cited by this paper
• Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

  2003cited by this paper
• Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies.

  2002cited by this paper
• Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation.

  2000cited by this paper
• Non‐transferrin‐bound iron induced by myeloablative chemotherapy

  1997cited by this paper
• Nontransferrin-bound iron in serum of patients receiving bone marrow transplants.

  1997cited by this paper
• Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy.

  1994cited by this paper

• From treatment to biology and back: managing iron overload in transfused hemoglobinopathies.

  2025cites this paper
• Iron toxicity and hematopoietic cell transplantation: do we understand why iron affects transplant outcome?

  2025cites this paper
• How I manage iron overload in the hemopoietic cell transplantation setting.

  2024cites this paper
• Management of iron overload: lessons from transfusion-dependent hemoglobinopathies.

  2024cites this paper
• Significant pituitary siderosis is common in transfusion dependent sickle cell disease.

  2024cites this paper
• Iron Chelation with Deferasirox suppresses the Appearance of LPI during Conditioning Chemotherapy prior to Allogeneic Stem Cell Transplantation.

  2022cites this paper
• Unbalance in Iron Metabolism in Childhood Leukemia Converges with Treatment Intensity: Biochemical and Clinical Analysis

  2021cites this paper
• Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa

  2019cites this paper
• Too much iron: A masked foe for leukemias.

  2019cites this paper
• Iron Toxicity and Hemopoietic Cell Transplantation: Time to Change the Paradigm

  2019cites this paper
• A new ferrous diflunisal complex and its effects on biopools of labile iron.

  2019cites this paper
• Pretransplant C-reactive protein, ferritin, albumin, and platelet count as prognostic biomarkers of hematopoietic stem cell transplantation outcome in hematological malignancies

  2018cites this paper
• Labile plasma iron as an indicator of patient adherence to iron chelation treatment.

  2018cites this paper
• Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post‐hematopoietic stem cell transplantation

  2018cites this paper
• Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

  2018cites this paper
• Impact of labile plasma iron and iron chelation on the viability of cultured mononuclear cells from patients undergoing autologous hematopoietic stem cell transplantation

  2017cites this paper
• Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies.

  2017cites this paper
• Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)

  2017cites this paper
• Impact of conditioning and engraftment on iron status in hematopoietic stem cell transplantation: Contribution of labile plasma iron.

  2016cites this paper
• Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

  2016cites this paper
• Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

  2015cites this paper
• Iron Toxicity in Hematopoietic Stem Cell Transplantation: Strike while the Iron Is Labile

  2013cites this paper